Lauxera Capital Partners
Lauxera Capital Partners is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Lauxera Capital Partners.
Lauxera Capital Partners is a company.
Key people at Lauxera Capital Partners.
Key people at Lauxera Capital Partners.
Lauxera Capital Partners is a transatlantic investment firm founded in 2020, headquartered in Paris with an office in San Francisco, specializing in growth-stage investments in healthtech, life sciences, medical devices, digital health, technology-enabled services, life science tools, diagnostics, and healthcare IT.[1][2][3][4] The firm's mission is to transform Europe's promising healthtech pioneers into global leaders by providing capital, operational expertise, and transatlantic support to scale commercially de-risked companies addressing large markets (€500m+).[1][2][4] With over €600 million in assets under management across 13 portfolio companies, Lauxera emphasizes hands-on partnership to drive organic growth, international expansion (especially into the US), regulatory navigation, and impact for patients and healthcare systems via its "Carried for Interest" program.[2][3]
Its investment philosophy prioritizes scientifically validated, revenue-generating businesses led by world-class managers, combining 50 years of healthcare investing experience and 35 years of scaling healthcare companies to improve efficiency, save lives, and reduce costs.[1][3][4] Lauxera significantly impacts the startup ecosystem by bridging European innovation with US market access, offering strategic guidance, talent management, and a growth toolbox that accelerates commercialization and external opportunities, as seen in its €50m investment in Acandis for stroke prevention devices.[2]
Lauxera Capital Partners was established in 2020 by entrepreneurial company builders and seasoned healthcare investors with deep operational roots in Europe and global expertise.[1][2][4][6] Key founding partner Alex Slack, based in Mill Valley, US, leads alongside a Paris-based team including Principal Charles Cornevin, CFO Anna Yang, and Investor Relations Manager Alix De Benedetti.[6] The firm emerged to address gaps in traditional European private equity by adopting a hands-on, operator-led model, drawing from decades of experience in building commercial organizations, mentoring teams, and navigating healthcare growth stages.[1][3][4]
Its evolution has focused sharply on healthtech since inception, rapidly scaling to manage over €600m and support 13 companies, with two funds closed by February 2022 and October 2025.[2][6][7] Pivotal early moves include investments like the January 2025 €50m commitment to Acandis, highlighting Lauxera's ability to attract partners valuing its US links, medical device expertise, and agile growth support.[2]
Lauxera rides the global healthtech boom, fueled by aging populations, post-pandemic digital adoption, and demand for cost-efficient care amid €500m+ addressable markets in devices, diagnostics, and IT.[1][3][4] Timing is ideal: scientific de-risking and revenue visibility in growth-stage firms align with maturing ecosystems, while US expansion counters Europe's scale limitations.[1][2] Market forces like regulatory convergence, AI-driven tools, and M&A activity favor its model, as seen in Acandis' US trials push.[2]
The firm influences the ecosystem by elevating European healthtech to global competitiveness, fostering transatlantic flows that attract follow-on capital and talent, and prioritizing patient outcomes to build sustainable franchises.[1][2][4]
Lauxera is poised for accelerated growth with recent fund closes and a €600m+ war chest, likely targeting more Series B/C healthtech deals in AI diagnostics, neurovascular tech, and data platforms amid rising US-Europe synergies.[2][3][6] Trends like personalized medicine, regulatory streamlining, and healthcare digitization will amplify its edge, potentially doubling AUM as portfolio exits materialize.[1][4] Its influence may evolve toward larger platforms and impact funds, solidifying as Europe's go-to healthtech scaler—transforming pioneers into leaders as envisioned from day one.[1][2]
